Key result
Metformin treatment significantly reduced the odds of major adverse cardiac events (adjusted OR 0.72) compared to non-insulin-sensitizing therapy in diabetic patients undergoing percutaneous coronary intervention.
Why the study?
Does metformin therapy reduce major adverse cardiac events in diabetic patients undergoing percutaneous coronary intervention?
Population
1,997 diabetic patients undergoing percutaneous coronary intervention.
Comparison
Metformin therapy vs Non-insulin-sensitizing therapy
Design
Cohort
Follow-up
9 months
Authors
Loading...
Does not support practice change in diabetic PCI patients; hypothesis-generating and requires RCTs to confirm benefit.
Cohort (n=1,997)
Yes
Does metformin therapy reduce major adverse cardiac events in diabetic patients undergoing percutaneous coronary intervention?
Effect estimate: OR 0.72 (95% CI 0.57 to 0.91)
Absolute Event Rate: 21% vs 24%
p-value: p=0.005
In diabetic patients undergoing percutaneous coronary intervention, metformin therapy is associated with a significantly lower incidence of death and myocardial infarction compared to non-insulin-sensitizing therapy.
Kao et al. (2004) conducted a cohort in Diabetes mellitus in patients undergoing percutaneous coronary intervention (n=1,997). Metformin therapy vs. Non-insulin-sensitizing therapy (sulfonylureas and/or insulin) was evaluated on Major adverse cardiac events (composite of myocardial infarction, death, and ischemia-driven target vessel revascularization) (OR 0.72, 95% CI 0.57 to 0.91, p=0.005). Metformin treatment significantly reduced the odds of major adverse cardiac events (adjusted OR 0.72) compared to non-insulin-sensitizing therapy in diabetic patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: